Evidence map›Paper›PMID 37582952›Full record

Trial reportNature medicine2023

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.

Alexander M Lesokhin, Michael H Tomasson, Bertrand Arnulf, Nizar J Bahlis, H Miles Prince, Ruben Niesvizky, Paula Rodrίguez-Otero, Joaquin Martinez-Lopez, Guenther Koehne, Cyrille Touzeau and 19 more

4 registry-linked trialsAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 391 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
391citing papers in PubMed, 14 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04649359 phase2active not recruitingnot on this map

Magnetismm-3 an open-label, multicenter, non-randomized phase 2 study of elranatamab (pf-06863135) monotherapy in participants with multiple myeloma who are refractory to at least one proteasome inhibitor, one immunomodulatory drug and one anti-cd38 antibody

TypeinterventionalSponsorPfizerRan2021 to 2026Enrolled187ConditionsMultiple MyelomaArmsElranatamab (PF-06863135)
NCT07094048 phase4recruitingnot on this mapstarted 2026, after this paper: background citation

Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager

TypeinterventionalSponsorCHU de Quebec-Universite LavalRan2026 to 2029Enrolled80ConditionsMultiple Myeloma Refractory, Relapsed Multiple MyelomaArmsTarget trough IgG level of 8-10 g/L, Target trough IgG level 4-6 g/L, No history of recurrent or severe infections and total IgG level higher or equal at 4 g/L
NCT07320326 not yet recruitingnot on this mapstarted 2025, after this paper: background citation

A Multi-center, Ambispective, Non-interventional, Observational, Registry Study of the Effectiveness of Elranatamab in Patients With Triple-class Exposed Relapsed/Refractory Multiple Myeloma in Routine Clinical Practice in China(ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab)

Typeobservational_patient_registrySponsorPeking University People's HospitalRan2025 to 2028Enrolled159ConditionsTCE-RRMMArmsElranatamab
NCT07524634 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Dose Schedule Investigation of B-Cell Maturation Antigen (BCMA) Bispecific Antibody, Elranatamab, for Treatment of Newly Diagnosed Light Chain Amyloidosis

TypeinterventionalSponsorCase Comprehensive Cancer CenterRan2026 to 2031Enrolled64ConditionsAmyloid Light-chain AmyloidosisArmsBCMA bispecific
3 · Its place in the literature

Who cites it

391 citing papers in PubMed, 14 syntheses or guidelines pooled it.

  1. Pooled it
  2. T-Cell Engagers TargetingInternational journal of molecular sciences · 2026
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

331 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Alexander M LesokhinDivision of Hematology and Oncology, Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College, New York City, NY, USA. lesokhia@mskcc.org.ORCID http://orcid.org/0000-0001-9321-702X
Michael H TomassonDepartment of Internal Medicine, University of Iowa, Iowa City, IA, USA.
Bertrand ArnulfHôpital Saint-Louis, Paris, France.
Nizar J BahlisArnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada.ORCID http://orcid.org/0000-0001-7353-7034
H Miles PrinceEpworth Healthcare and University of Melbourne, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-0058-2448
Ruben NiesvizkyWeill Cornell Medical College/New York Presbyterian Hospital, New York City, NY, USA.
Paula Rodrίguez-OteroClinica Universidad de Navarra, Madrid, Spain.
Joaquin Martinez-LopezHospital Universitario 12 de Octubre, Madrid, Spain.ORCID http://orcid.org/0000-0001-7908-0063
Guenther KoehneMiami Cancer Institute, Miami, FL, USA.
Cyrille TouzeauUniversity Hospital of Nantes, Nantes, France.
Yogesh JethavaIndiana Blood & Marrow Transplant, Indianapolis, IN, USA.
Hang QuachUniversity of Melbourne, St. Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.
Julien DepausUniversité Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium.
Hisayuki YokoyamaTohoku University Graduate School of Medicine, Sendai, Japan.
Afshin Eli GabayanBeverly Hills Cancer Center, Beverly Hills, CA, USA.
Don A StevensNorton Cancer Center, Louisville, KY, USA.
Ajay K NookaWinship Cancer Institute, Atlanta, GA, USA.ORCID http://orcid.org/0000-0003-4165-6869
Salomon ManierLille University Hospital and INSERM UMR-S1277, Lille, France.
Noopur RajeMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Shinsuke IidaDepartment of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Marc-Steffen RaabHeidelberg Myeloma Center, Department of Hematology/Oncology, Heidelberg University Hospital, Heidelberg, Germany.ORCID http://orcid.org/0000-0003-4181-6922
Emma SearleThe Christie Hospital, The University of Manchester, Manchester, UK.
Eric LeipPfizer Inc, Cambridge, MA, USA.
Sharon T SullivanPfizer Inc, Cambridge, MA, USA.
Umberto ContePfizer Inc, New York, NY, USA.
Mohamed ElmeliegyPfizer Inc, San Diego, CA, USA.
Akos CziberePfizer Inc, New York, NY, USA.
Andrea ViqueiraPfizer SLU, Madrid, Spain.
Mohamad MohtySorbonne University, Hôpital Saint-Antoine, and INSERM UMRs938, Paris, France.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Jon C.D. Houtman · 2000 to 2026
$70.0M
NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA086862
6 · The paper itself

Abstract

Elranatamab is a humanized B-cell maturation antigen (BCMA)-CD3 bispecific antibody. In the ongoing phase 2 MagnetisMM-3 trial, patients with relapsed or refractory multiple myeloma received subcutaneous elranatamab once weekly after two step-up priming doses. After six cycles, persistent responders switched to biweekly dosing. Results from cohort A, which enrolled patients without prior BCMA-directed therapy (n = 123) are reported. The primary endpoint of confirmed objective response rate (ORR) by blinded independent central review was met with an ORR of 61.0% (75/123); 35.0% ≥complete response. Fifty responders switched to biweekly dosing, and 40 (80.0%) improved or maintained their response for ≥6 months. With a median follow-up of 14.7 months, median duration of response, progression-free survival and overall survival (secondary endpoints) have not been reached. Fifteen-month rates were 71.5%, 50.9% and 56.7%, respectively. Common adverse events (any grade; grade 3-4) included infections (69.9%, 39.8%), cytokine release syndrome (57.7%, 0%), anemia (48.8%, 37.4%), and neutropenia (48.8%, 48.8%). With biweekly dosing, grade 3-4 adverse events decreased from 58.6% to 46.6%. Elranatamab induced deep and durable responses with a manageable safety profile. Switching to biweekly dosing may improve long-term safety without compromising efficacy. ClinicalTrials.gov identifier: NCT04649359 .

Indexed as

Multiple MyelomaB-Cell Maturation AntigenHumansProgression-Free SurvivalRemission InductionB-Cell Maturation Antigen

Identifiers

PMID37582952
PMCPMC10504075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.